NK cells have been genetically modified to produce secretory IL-15 (sIL-15) or mbIL-15 and then evaluated in several preclinical and clinical models of acute myeloid leukemia (AML) (62–64), lymphoma (65), pancreatic cancer (66), and multiple myeloma (MM) (64); the NK cell survival rates and levels of antitumor efficacy were significantly improved (Figure 2). Here, IL15 is linked to acute myeloid leukemia.